DoubleChecks

What was claimed

Mel Gibson isn't lying; our new study found 84% of cancer patients on ivermectin + mebendazole had complete remission, tumor shrinkage or halted growth after 6 months

Our verdict

Needs caution

The study reports an 84.4% clinical benefit ratio, but that includes stable disease and is based on self-reported outcomes in an uncontrolled observational cohort. It does not establish that the drugs caused remission or tumor shrinkage. The 84.4% CBR combines three different outcomes: 32.8% no evidence of disease, 15.6% regression, and 36.1% stable disease. Only 48.4% had the strongest outcomes (remission or regression). Grouping stable disease with remission inflates the impression of efficacy.

1 of 3 AI systems agree14 sources citedChecked Aug 29, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

Complete remission, tumor shrinkage or halted growth occurred in 84% of patients

Misleading90%
1 AI checked

A new study found 84% of cancer patients on ivermectin plus mebendazole had complete remission, tumor shrinkage, or halted growth after 6 months.

Misleading96%
4 of 5 AIs agree·Perplexity: Incorrect

Mel Gibson isn't lying (implying his endorsement of this treatment is factually correct).

Can’t verify60%
All 2 AIs agree

Verified against 14 sources

x.compubmed.ncbi.nlm.nih.govyahoo.comsanarelab.sciencetwg.healthx.comyoutube.comtherealfacthunter.comyoutube.comsanarelab.sciencex.comfagronacademy.uspccarx.comfacebook.com

Detailed Analysis

The claim overstates weak observational data as proof of efficacy. The cited study reports a self-reported clinical benefit ratio, not verified complete remission, and it lacked a control group and independent outcome confirmation.[2] [3] [10]

Why this verdict

  • The claim overstates weak observational data as proof of efficacy.
  • The cited study reports a self-reported clinical benefit ratio, not verified complete remission, and it lacked a control group and independent outcome confirmation.[2] [3] [10]

Claims checked

The study showed complete remission.

Incorrect95%
The reported endpoint was clinical benefit, not verified complete remission for 84% of patients. Secondary summaries note 32.8% reported no evidence of disease, but this was self-reported and not independently verified.[2] [10] [11]

This claim may mislead readers without added context.

The study demonstrated halted tumor growth.

Misleading97%
Stable disease was included in the 84.4% clinical benefit ratio, but stable disease is not proof that treatment halted growth. The study design cannot distinguish treatment effect from natural disease course or concurrent therapies.[2] [3] [10]

This claim may mislead readers without added context.

A new study found 84% of cancer patients on ivermectin plus mebendazole had complete remission, tumor shrinkage, or halted growth after 6 months.

Misleading98%
The study reports an 84.4% clinical benefit ratio, but that includes stable disease and is based on self-reported outcomes in an uncontrolled observational cohort. It does not establish that the drugs caused remission or tumor shrinkage.[2] [3] [10]

This claim may mislead readers without added context.

What other AI think

The claim misrepresents a flawed observational study as definitive evidence. While an 84.4% CBR figure exists, it comes from self-reported outcomes in a study with significant confounding (patients used multiple concurrent treatments), high dropout rates, and acknowledged limitations. The claim falsely attributes this to "our new study" and conflates it with Mel Gibson's anecdotal claims, presenting hypothesis-generating findings as established fact.

Why this verdict

  • The claim misrepresents a flawed observational study as definitive evidence.
  • While an 84.4% CBR figure exists, it comes from self-reported outcomes in a study with significant confounding (patients used multiple concurrent treatments), high dropout rates, and acknowledged limitations.
  • The claim falsely attributes this to "our new study" and conflates it with Mel Gibson's anecdotal claims, presenting hypothesis-generating findings as established fact.

Claims checked

Complete remission, tumor shrinkage or halted growth occurred in 84% of patients

Misleading90%
The 84.4% CBR combines three different outcomes: 32.8% no evidence of disease, 15.6% regression, and 36.1% stable disease. Only 48.4% had the strongest outcomes (remission or regression). Grouping stable disease with remission inflates the impression of efficacy.

This claim may mislead readers without added context.

Our new study found 84% of cancer patients on ivermectin + mebendazole had complete remission, tumor shrinkage or halted growth after 6 months

Misleading95%
The 84.4% figure is real but represents self-reported outcomes in an observational study with major limitations: only 61.9% follow-up completion, concurrent use of chemotherapy/radiation/surgery by most patients, and acknowledged selection bias. The study authors explicitly state findings are 'hypothesis-generating' and not proof of efficacy.

This claim may mislead readers without added context.

Mel Gibson isn't lying

Can’t verify60%
Gibson made anecdotal claims about three friends, which cannot be verified or falsified without medical records. However, his claims are not supported by the clinical evidence, which remains limited to observational studies.
The 84% figure matches a recent prospective observational cohort report that reported an 84.4% clinical benefit ratio at six months. However that outcome was self‑reported, heterogeneous, and uncontrolled, so reporting it as definitive evidence that the drugs caused remissions or tumor shrinkage is misleading.

Why this verdict

  • The 84% figure matches a recent prospective observational cohort report that reported an 84.4% clinical benefit ratio at six months.
  • However that outcome was self‑reported, heterogeneous, and uncontrolled, so reporting it as definitive evidence that the drugs caused remissions or tumor shrinkage is misleading.

Claims checked

A new study found 84% of cancer patients on ivermectin + mebendazole had complete remission, tumor shrinkage or halted growth after 6 months.

Misleading92%
A recent prospective observational cohort reported an 84.4% ‘clinical benefit’ at six months (including regression, no evidence of disease, or disease stabilization). But the data were self‑reported, from a heterogeneous uncontrolled cohort, and cannot establish that the drug combination caused those outcomes.

This claim may mislead readers without added context.

Mel Gibson isn't lying (implying his endorsement of this treatment is factually correct).

Can’t verify60%
Whether Mel Gibson’s statements are truthful depends on which specific claims he made and whether he intended to imply causation; the observational study cannot confirm the treatment’s efficacy, so endorsement as ‘true’ is not verifiable from available evidence.

Share this result

Try DoubleChecks